Posted on 12/19/19
Exact Sciences Should Benefit from Pfizer’s News Today
This morning, Pfizer (NYSE:PFE) announced that the Food and Drug Administration granted priority review status to its supplemental New Drug Application (sNDA) for its Braftovi in . . .
Posted on 12/18/19
Soligenix to Receive $850,000 in Non-Dilutive Funding
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an . . .
Posted on 12/18/19
New York Life to Acquire Cigna’s Group Life and Disability Insurance Business
NEW YORK & BLOOMFIELD, Conn.--(BUSINESS WIRE)--New York Life, America’s largest mutual life insurer, and Cigna, a leading global health service company, announced today that they have . . .
Posted on 12/18/19
7 Reasons Teladoc Will Be a Top Growth Stock in 2020
With interest rates and inflation near record lows, recession concerns subsiding, and the upcoming election providing an incentive for the Trump administration to tamp down worries . . .
Posted on 12/18/19
Pfizer: A New Science-Based Pharma Wonder
SummaryPfizer took a huge price drop at the end of July after the company announced the divestment of the Upjohn unit.Upjohn unit divesting could bring value . . .
Posted on 12/18/19
FDA Advisory Committee Backs Merck's Keytruda for NMIBC
The FDA's Oncologic Drugs Advisory Committee voted 9-4 that the benefits outweigh the risks of Merck's (NYSE:MRK) Keytruda (pembrolizumab) for the treatment of bacillus Calmette-Guérin-unresponsive, high-risk, . . .
Posted on 12/18/19
Merck Adds To Aquaculture Portfolio With Vaki Purchase
Merck's (NYSE:MRK) animal health division acquires Vaki, a maker of fish farming and wild fish conservation monitoring equipment, from Pentair (NYSE:PNR) to broaden Merck's aquaculture portfolio.Financial . . .
Posted on 12/17/19
ContraFect Corp. Prices $10M Public Offering of Common Stock
YONKERS, N.Y., Dec. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the . . .
Posted on 12/17/19
TMRW Life Sciences Raises $25 Million In Series B Funding Led By 5AM Ventures
TMRW Life Sciences, creator of ivfOS, an integrated platform for automated, software-guided embryology and cryo-management
Posted on 12/17/19
Triplet Therapeutics Launches with $59M In Financing
Triplet Therapeutics, Inc., a biotechnology company harnessing human genetics to develop treatments for repeat expansion disorders at their source
Posted on 12/17/19
Merck's Latest $2.7-Billion Buy Of ArQule Brings About Precision Targeted And Diversified Approach To Cancer Therapy
SummaryMerck announced that it would spend $2.7 billion to acquire ArQule, which is a precision-focused biotech targeting indications with high unmet medical need.The acquisition brings about . . .
Posted on 12/17/19
Pfizer: A New Science-Based Pharma Wonder
SummaryPfizer took a huge price drop at the end of July after the company announced the divestment of the Upjohn unit.Upjohn unit divesting could bring value . . .
Posted on 12/17/19
Bristol-Myers Placed A Big Bet On Celgene’s Pipeline. Will It Pay Off For Investors?
On Nov. 20, Bristol-Myers Squibb (NYSE:BMY) announced the completion of its $74 billion acquisition of Celgene (NASDAQ:CELG). Bristol-Myers' strategy centers on merging an innovative, agile biotechnology . . .
Posted on 12/16/19
Consonance Capital Partners To Sell Enclara Healthcare To Humana
NEW YORK & PHILADELPHIA--(BUSINESS WIRE)--Consonance Capital Partners, a leading healthcare-focused private equity fund, announced today that it signed a definitive agreement to sell Enclara Healthcare, along . . .
Posted on 12/16/19
Merck's Strong Pipeline Projects High Growth Potential
SummaryThe stock represents good value with an estimated upside of 15.15% with a target price of $102.44, backed by strong fundamentals.Merck & Co is expected to . . .
Posted on 12/16/19
Better Buy: Eli Lilly vs. Merck
Merck (NYSE:MRK) and Eli Lilly (NYSE:LLY) are two of the largest pharmaceutical companies in the world, and both provide decent prospects for investors. Comparing the two . . .
Posted on 12/16/19
Better Buy: AbbVie vs. Merck
AbbVie (NYSE:ABBV) ranks as one of the biggest pharmaceutical stocks on the market. But it's still a lot smaller than Merck (NYSE:MRK). Bigger has proven to . . .
Posted on 12/16/19
Why Teladoc Health Is Risky to Own
Teladoc Health (NYSE:TDOC) operates a virtual healthcare service, delivered primarily through telephone and videoconferencing. Users receive medical opinions, treatment instructions, on-demand remote care, mental health support, . . .
Posted on 12/16/19
Intercept Provides Regulatory Update
NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat . . .
Posted on 12/16/19
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
WARREN, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on . . .
Posted on 12/16/19
Capital Health Medical Group Adds Bucks County OB/GYN Practice to Growing Team of Specialists
Capital Health Medical Group is pleased to announce the addition of Women's Specialists of Bucks County, a comprehensive OB/GYN practice, to its growing network of specialty . . .
Posted on 12/15/19
HealthSTAR Communications Named One of the Most Innovative Companies of 2019 by PM360
MAHWAH, N.J.--(BUSINESS WIRE)--PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named HealthSTAR Communications as one . . .
Posted on 12/15/19
Rocket Pharmaceuticals Closes Public Offering
NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the . . .
Posted on 12/13/19
After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
Bristol-Myers Squibb's (NYSE:BMY) acquisition of the biopharmaceutical company Celgene -- one of the most expensive acquisitions in the history of the pharmaceutical industry -- didn't exactly . . .
Posted on 12/12/19
OncoSec CEO Daniel O’Connor Sends Letter to Fellow Shareholders
SAN DIEGO & PENNINGTON, N.J.--(BUSINESS WIRE)--Daniel O’Connor, President, Director & CEO of OncoSec Medical Incorporated (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today sent the . . .
New York
